<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02721784</url>
  </required_header>
  <id_info>
    <org_study_id>15/0342</org_study_id>
    <nct_id>NCT02721784</nct_id>
  </id_info>
  <brief_title>Serial mpMRI (Multi Parametric Magnetic Resonance Imaging) Scanning in Prostate Cancer After Androgen Deprivation Therapy and RadioTherapy</brief_title>
  <acronym>SMART</acronym>
  <official_title>Serial mpMRI (Multi Parametric Magnetic Resonance Imaging) Scanning in Prostate Cancer After Androgen Deprivation Therapy and RadioTherapy (SMART)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University College, London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The evaluation of the radiological changes in localised or locally advanced prostate cancer&#xD;
      after androgen deprivation therapy and external beam radiotherapy using multi-parametric MRI&#xD;
      (multi parametric magnetic resonance imaging) and VERDICT (Vascular, Extracellular and&#xD;
      Restricted Diffusion for Cytometry in Tumours) sequences.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      External beam radiotherapy (EBRT) fails to eradicate prostate cancer in 24-33% of cases.&#xD;
      Response is monitored solely by testing serum prostate specific antigen (PSA), with&#xD;
      biochemical failure following radiotherapy defined as a prostate specific antigen (PSA) level&#xD;
      of 2 ng/ml above the nadir.&#xD;
&#xD;
      T2 and Dynamic Contrast Enhanced (DCE) MRI have been shown to be able to detect the&#xD;
      recurrence of prostate cancer following radiotherapy. Changes seen in Apparent Diffusion&#xD;
      Coefficient (ADC) variables post-treatment have potential use in monitoring disease response&#xD;
      to radiotherapy but the natural history of these changes during and after treatment remains&#xD;
      uncertain and warrants further investigation.&#xD;
&#xD;
      This study investigates the feasibility of using multi-parametric MRI (mpMRI) and novel&#xD;
      diffusion-weighted sequences called VERDICT (Vascular, Extracellular and Restricted Diffusion&#xD;
      for Cytometry in Tumours) at various stages during the treatment of prostate cancer with&#xD;
      radiotherapy. Patients will be first scanned before androgen deprivation therapy (ADT)&#xD;
      starts, then 3 weeks before the start of radiotherapy, again in week 6 of radiotherapy and&#xD;
      once more 6 months after the end of radiotherapy. In addition, all patients entered into the&#xD;
      study will already have had a mpMRI scan prior to prostate biopsy as part of their standard&#xD;
      care.&#xD;
&#xD;
      Multi-parametric MRI and VERDICT sequences may reveal changes in the tumour and normal&#xD;
      prostate before a detectable PSA increase. This could allow for their use in response&#xD;
      assessment following radiotherapy and androgen deprivation treatment. If such clinical&#xD;
      utility is proven, referral for salvage treatment using High Intensity Focussed Ultrasound&#xD;
      (HIFU), cryotherapy or salvage radical prostatectomy may be expedited.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of changes in MRI ADC value</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of changes in mpMRI tumour volume (cubic centimetres)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of changes in enhancement measured as a transfer constant (KTrans) value</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Pre- and Post- Radiotherapy MRI</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>mpMRI/VERDICT sequences to be preformed pre- and post- EBRT (external beam radiotherapy) according to the following schedule:&#xD;
Pre-Androgen Deprivation Therapy 3 weeks before radiotherapy 6 week after starting radiotherapy 6 Months after starting radiotherapy&#xD;
External Beam Radiotherapy to be given after 3 months of androgen deprivation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>mpMRI/VERDICT</intervention_name>
    <description>Combined MRI sequences of T2, DCE, Diffusion and VERDICT</description>
    <arm_group_label>Pre- and Post- Radiotherapy MRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>External Beam Radiotherapy</intervention_name>
    <description>78Gy (Gray) to Prostate +/- Pelvic</description>
    <arm_group_label>Pre- and Post- Radiotherapy MRI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Targeted or Concordant biopsy confirmed prostate cancer&#xD;
&#xD;
          2. Pre-biopsy mpMRI scan of the prostate undertaken at University College London Hospital&#xD;
             (UCLH)&#xD;
&#xD;
          3. Agrees to have ADT and EBRT&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Treatment within the previous 6 months with any form of hormones (including 5-alpha&#xD;
             reductase inhibitors)&#xD;
&#xD;
          2. Evidence of metastatic disease&#xD;
&#xD;
          3. Prior local intervention to the prostate&#xD;
&#xD;
          4. Unable to give informed consent&#xD;
&#xD;
          5. Any prosthesis (including hip replacements) which could cause artefacts degrading the&#xD;
             quality of the imaging&#xD;
&#xD;
          6. Contraindication to gadolinium contrast agent&#xD;
&#xD;
          7. Unable to tolerate an MRI&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Taimur T Shah, MBBS,BSc,MRCS</last_name>
    <phone>02076799092</phone>
    <email>taimur.shah@ucl.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Urology Research Group</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>NW1 2PS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Taimur T Shah, MBBS,BSc,MRCS</last_name>
      <phone>02076799092</phone>
      <email>taimur.shah@ucl.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Anita Mitra, MBBS MD FRCR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>January 4, 2016</study_first_submitted>
  <study_first_submitted_qc>March 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2016</study_first_posted>
  <last_update_submitted>October 25, 2016</last_update_submitted>
  <last_update_submitted_qc>October 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MRI</keyword>
  <keyword>Radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

